CLK Inhibitors - Market Size, Target Population, Competitive Landscape & Market Forecast - 2036

Key Highlights

• CLK (CDC-like kinase) inhibitors target the CLK1, CLK2, CLK3, and CLK4 isoforms, which regulate pre-mRNA splicing via SR protein phosphorylation. They are mainly being developed for cancer treatment, especially in tumors with spliceosome mutations or splicing dependency.
• Among the four family members of CLKs, CLK1 has been structurally and functionally well characterized. CLK1, also termed STY, has been identified to be auto-phosphorylated at Ser/Thr/Tyr residues and phosphorylates Ser residues of its substrates.
• Recent studies have linked bispecific tyrosine phosphorylation-regulated kinases (DYRK1A, 1B, 2-4) and CDC2-like kinases (CLK1-4) to various neurological disorders in humans. Therefore, developing potent and selective inhibitors of these kinases and testing them as therapeutic agents is encouraging.
• Emerging biotech companies are actively advancing CLK inhibitor programs, reflecting growing momentum in RNA splicing-targeted oncology. Chordia Therapeutics’s Rogocekib (CTX-712), is a first-in-class pan-CLK inhibitor that has demonstrated encouraging anti-tumor activity in early clinical studies. BlossomHill Therapeutics’s BH-30236, is being evaluated for hematological malignancies such as Acute Myeloid Leukemia (AML) and myelodysplastic syndromes. In parallel, Biosplice Therapeutics is advancing Lorecivivint (SM04690) and Cirtuvivint (SM08502), Curis is developing Emavusertib (CA-4948).

The “CLK Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast - 2036” report delivers an in-depth understanding of CLK Inhibitors, addressable patient pool, competitive landscape, and future market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.

The CLK Inhibitors market report provides insights around existing treatment practices in patients with CLK Inhibitors, approved (if any) and emerging CLK Inhibitors, market share of individual therapies, patient pool eligible for treatment with CLK Inhibitors, along with current and forecasted 7MM CLK Inhibitors market size from 2022-2036 by therapies and by indication. The report also covers current unmet needs and challenges while incorporating new classes in treatment paradigm, variations in accessibility and acceptability of new CLK Inhibitors in different geographies, along with insights on CLK Inhibitors pricing reimbursements to curate the best opportunities and assess the market’s potential.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain), and the UK
• Japan

Study Period: 2022-2036

CLK Inhibitors Overview

CLK (CDC-like kinase) inhibitors target the CLK1, CLK2, CLK3, and CLK4 isoforms, which regulate pre-mRNA splicing via SR protein phosphorylation. They are mainly being developed for cancer treatment, especially in tumors with spliceosome mutations or splicing dependency.

Among the four family members of CLKs, CLK1 has been structurally and functionally well characterized. CLK1, also termed STY, has been identified to be auto-phosphorylated at Ser/Thr/Tyr residues and phosphorylates Ser residues of its substrates.

Recent studies have linked bispecific tyrosine phosphorylation-regulated kinases (DYRK1A, 1B, 2-4) and CDC2-like kinases (CLK1-4) to various neurological disorders in humans. Therefore, developing potent and selective inhibitors of these kinases and testing them as therapeutic agents is encouraging.

Epidemiology Insights

• According to analysis, the total incident cases AML were approximately 44,000 in the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
• In 2025 the prevalent cases of knee osteoarthritis were ~51,495,300 million in the 7MM.
• According to analysis, the total number of incident cases of pancreatic cancer in the US were approximately ~64,000 in 2025.
• Exocrine pancreatic cancer is more common than the neuroendocrine pancreatic cancer accounting for more than 90% of total cases.
• In 2025 the total incidence cases of colorectal cancer were ~570,800 in the 7MM.
• In 2025, Germany had nearly 6,973,000 diagnosed prevalent cases of knee osteoarthritis.

CLK Inhibitors Drug Chapters

The drug chapter segment of the CLK Inhibitors report encloses a detailed analysis of marketed therapies and late-stage (Phase III and Phase II) therapies. It also helps understand the CLK Inhibitors clinical trial details, pharmacological action, agreements and collaborations related to CLK Inhibitors, their approval timelines, patent details, advantages and disadvantages, latest news and press releases.

CLK Inhibitors Emerging Drugs

Lorecivivint (SM04690): Biosplice Therapeutics

Lorecivivint is a small-molecule suspension intended to be injected 1-2 times per year into the knee joint. Lorecivivint, evaluated in 11 clinical trials, significantly improved pain and function in patients with a very good safety profile. Results from Biosplice’s Phase III OA-07 trial also showed that lorecivivint led to improvements in medial joint space width (JSW) on imaging over multiple years.

In January 2026, Biosplice Therapeutics announced today that it has submitted its NDA to the FDA for approval of its novel therapy for the treatment of knee osteoarthritis.

Rogocekib (CTX-712): Chordia Therapeutics

Highly selective for CLK, CTX-712 is an orally available, first-in-class pan-CLK inhibitor. In several preclinical models, it have confirmed that it can induce cancer cell death in vitro, and induce anti-tumor effects in vivo. CTX-712 was confirmed proof of concept (POC) in a first in human phase I clinical trial conducted in Japan. It is currently being evaluated in early-phase clinical trials, including a Phase I/II study in patients with refractory or relapsed AML and myelodysplastic syndromes. Rogocekib for the treatment of r/r AML had been granted Orphan Drug Designation (ODD) by the US FDA.

BH-30236: BlossomHill Therapeutics

BH-30236 is a novel, orally available, macrocyclic, ATP-competitive, highly potent and selective inhibitor of CDC-like kinase (CLK) designed to address dysregulated RNA splicing events that drive tumor growth and disease progression. In preclinical studies, BH-30236 demonstrated in vitro efficacy in patient-derived AML cells, including cells insensitive to venetoclax. BH-30236 is currently being evaluated as a monotherapy or in combination with venetoclax in a first-in-human, Phase I/Ib dose escalation study in adult participants with relapsed or refractory AML or higher-risk myelodysplastic syndrome (HR-MDS).

Recent Developments in the CLK Inhibitors Market

• In March 2026, BlossomHill Therapeutics announced that it will present new preclinical data supporting the continued advancement of its clinical program BH-30236, an oral CLK inhibitor for hematologic malignancies.
• In January 2026, Chordia Therapeutics announced that the final, fully formatted version, including completed figures and tables, of the peer-reviewed article summarizing the final results of the Phase I trial of rogocekib (CTX-712), for patients with hematologic malignancies conducted in Japan, had been published in Blood Advances.

Drug Class Insights

The Drug Class Insights section will provide comprehensive information on CLK Inhibitors as a class. This will include a broad overview of the class and its role in treating specific conditions. Insights may cover the historical clinical development of CLK Inhibitors, their mechanism of action, their subtypes and future commercial prospects. Additionally, the section will provide detailed information about current trends, challenges, and future prospects for this class of drugs.

CLK Inhibitors Market Outlook

This section will include details on changing CLK Inhibitors market dynamics post initiation of clinical development activities of the inhibitor. It will also provide a detailed summary and comparison of all the therapies being developed by leading players in this space. This section will highlight the advantages of one therapy over the other after assessment based on parameters such as data availability in the form of safety and efficacy, number of patients enrolled in each trial, and trial’s inclusion criteria. There will be a Key focus on the importance of development and need for the commercial success of these targeted therapies to achieve treatment goals that physicians and patients are looking for. It will also sum up all the early stage players active in this space.

CLK Inhibitors Drugs Uptake

This section focuses on the uptake rate of potential CLK Inhibitors already launched and expected to be launched in the market during 2022-2036, which depends on the competitive landscape, safety, efficacy data, and order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.

CLK Inhibitors Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III and Phase II stages. It also analyzes key players involved in developing targeted therapeutics.

CLK Inhibitors Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for CLK Inhibitors.

KOL Views

To keep up with current and future market trends, we incorporate Key physicians, Therapy Area Researcher’s, and other Industry Experts’ opinions working in the domain through primary research to fill in the data gaps and validate our secondary research. 25+ Key Opinion Leaders (KOLs) were contacted for insights on CLK Inhibitors’ incorporation in the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along with challenges related to accessibility.

Qualitative Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Analyst views. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the analyst’s discretion and assessment of the cost analysis and existing and evolving treatment landscape.

Market Access and Reimbursement

This section will include insights around the standard HTA pricing, recent reformations in 2024 and modifications in reimbursement process in the 7MM. For example, In the United States, a multi payer model exists when it comes to drug pricing regime, which is currently undergoing significant changes, with recent federal legislation, such as the Prescription Drug Pricing Reform provisions of the Inflation Reduction Act, significantly altering the pricing regime under certain federal programs. Whereas in Germany, the market access differs from the systems followed in many other countries as no pricing and reimbursement approval is required during launch of a new therapy.

Moreover, this section will also provide details on reimbursement of approved therapy, if any.

Scope of the Report

• The report covers a segment of key events, an executive summary, target patient pool, epidemiology and market forecasts, information around patient journey and varying biomarker testing rates
• Additionally, an all-inclusive account of the current and emerging therapies drug chapters, insights on CLK Inhibitors addressable patient pool
• A detailed review of the CLK Inhibitors market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, and treatment preferences that help in shaping and driving the 7MM CLK Inhibitors market.
• Market Size of Inhibitors by therapies and indication will be provided

CLK Inhibitors Report Key Strengths

• 11 Years CLK Inhibitors Market Forecast
• The 7MM Coverage
• CLK Inhibitors Competitive Landscape of current and emerging therapies
• CLK Inhibitors Total Addressable patient population
• Drugs Uptake and Key Market Forecast Assumptions
• Approved and Emerging therapy Profiles
• Physician’s perspectives/KOL opinions
• Biomarker testing and Patient journey
• Qualitative Analysis (SWOT and Analyst Views)
• CLK Inhibitors Market Size by therapy and indication
• Existing and Future Market Opportunity
• Unmet Needs

FAQs

• What was the CLK Inhibitors total market size, the market size by therapies, market share (%) distribution in 2022, and what would it look like by 2036? What are the contributing factors for CLK Inhibitors market growth?
• Which KRAS Inhibitor is going to be the largest contributor by 2036?
• What is the market access and reimbursement scenario of CLK Inhibitors?
• What are the pricing variations among different geographies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?

Reasons to Buy

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the CLK Inhibitors Market.
• Understand the existing CLK Inhibitors market opportunities and future trends in varying geographies
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders’ perspectives around the accessibility and acceptability of emerging treatment options along with unmet need of current therapies
• Details on report methodology, top indications covered, market assumptions, patient journey and KOLs to strengthen the pharmaceutical companies’ development and launch strategy.

This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.